Massachusetts based Moderna Inc.’s experimental vaccine against the contagious coronavirus has shown encouraging results in early testing. This has moved the global fight against Covid 19 an inch towards some positive progression.
Study volunteers given either a low or medium dose of the vaccine had antibodies similar to those seen in people who have recovered from COVID-19.
As per international press reports, the next phase of the study led by the U.S. National Institutes of Health, researchers will try to determine which dose is best for a definitive experiment that they aim to start in July. The vaccine seems safe, the company said, but much more extensive testing is needed to see if it remains so. A high dose version is being dropped after spurring some short-term side effects.